News & Updates
Filter by Specialty:
PAOLA-1 at 5 years: Maintenance olaparib + bevacizumab support long-term remission in HRD-positive ovarian cancer
22 Apr 2024
byNatalia Reoutova
Post hoc analysis of the phase III PAOLA-1/ENGOT-ov25 trial reports respective 5-year progression-free survival (PFS) rates of 72 percent vs 28 percent and 5-year overall survival (OS) rates of 88 percent vs 61 percent for maintenance olaparib plus bevacizumab vs bevacizumab alone in lower-risk homologous recombination deficiency (HRD)–positive patients with newly diagnosed advanced ovarian cancer.
PAOLA-1 at 5 years: Maintenance olaparib + bevacizumab support long-term remission in HRD-positive ovarian cancer
22 Apr 2024
Gene profiling of skin lesions improves diagnosis of allergic contact dermatitis
19 Apr 2024
Analysing molecular signatures from active skin lesions aids in the stratification of patients with contact dermatitis (CD) and helps identify those with allergic CD, suggests a study.
